Mr. Gary Thompson reports
M PHARMACEUTICAL ANNOUNCES ENGAGEMENT OF INVESTMENT BANKING FIRM MAXIM GROUP LLC TO PROVIDE CORPORATE FINANCE ADVISORY SERVICES
M Pharmaceutical Inc. has engaged Maxim Group LLC, a leading full-service investment banking, securities and wealth management firm headquartered in New York, as the company's corporate finance adviser to provide strategic advisory services, in particular related to assisting in the development of a financial strategy to restructure M Pharma's current debt facilities and to act as lead adviser for possible future debt and equity financings. Maxim will also focus on assisting M Pharma in creating and executing new strategies for maximizing shareholder value through its full scope of investment banking services.
Pursuant to the agreement commencing on April 1, 2017, Maxim will receive on the first day of each month of the six-month term $7,500 (U.S.). In addition, the agreement entitles Maxim to specific success-based compensation, along with the issuing of 4.5 million shares of the M Pharma's common shares.
"We chose to partner with the Maxim Group because of their successful track record as a respected, full-service investment banking firm and look forward to their advice and guidance with respect to our important strategic decisions," said Gary A. Thompson, president and chief executive officer of M Pharma. "Their health care team will be an invaluable partner in the execution of our growth strategy," added Mr. Thompson.
"M Pharmaceutical has assembled an exciting portfolio of technologies with significant revenue potential that target important health and wellness issues. We look forward to working with Gary and his team to develop and implement a comprehensive capital markets strategy," said John Shaw, senior managing director at Maxim Group LLC.
About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity, weight management, and female health and wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, and assets from 40J's LLC, the company is scheduled to launch its Food and Drug Administration-cleared fertility product branded as ToConceive some time in the second quarter of 2017.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.